Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
Metrics: PDF 2558 views | HTML 3089 views | ?
Yusuke Inoue1,2, Katsuhiro Yoshimura1,2, Nobuya Kurabe1, Tomoaki Kahyo1, Akikazu Kawase3, Masayuki Tanahashi4, Hiroshi Ogawa5, Naoki Inui2,6, Kazuhito Funai3, Kazuya Shinmura1, Hiroshi Niwa4, Takafumi Suda2, Haruhiko Sugimura1
1Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
2Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
3First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
4Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan
5Department of Pathology, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan
6Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Haruhiko Sugimura, email: email@example.com
Keywords: CD73, A2AR, adenosine, prognosis, non-small-cell lung cancer
Received: September 20, 2016 Accepted: December 01, 2016 Published: January 02, 2017
In immune cells, CD73 dephosphorylates and converts extracellular AMP into adenosine, which binds the A2A adenosine receptor (A2AR). Blockade of this interaction, which induces an immunosuppressed niche in the tumor microenvironment, represents a potential novel treatment strategy. The clinical significance of CD73 and A2AR expression in non-small-cell lung cancer (NSCLC), however, has yet to be thoroughly investigated. Here we evaluated CD73 and A2AR protein expression levels using immunohistochemistry in tissue microarrays containing 642 resected NSCLC specimens. Furthermore, we compared the expression profiles of 133 paired primary tumors and lymph node metastases. CD73 and A2AR expression levels were significantly higher in females than in males, in never smokers than in ever smokers, and in adenocarcinomas than in squamous cell carcinomas. Among adenocarcinomas, significantly higher CD73 and A2AR expression was observed in TTF-1-positive and mutant EGFR-positive tumors than in their counterparts. Compared with CD73, A2AR expression was more inconsistent between primary tumors and lymph node metastases. Among NSCLC patients, high CD73 expression was an independent indicator of poor prognosis in multivariate Cox regression analyses for overall survival [hazard ratio (HR), 2.18; 95% confidence interval (CI), 1.38–3.46] and recurrence-free survival (HR, 2.05; 95% CI, 1.42–2.95). In contrast, high A2AR expression was an independent predictor of favorable prognosis for overall survival (HR, 0.70; 95% CI, 0.50–0.98) and recurrence-free survival (HR, 0.74; 95% CI, 0.56–0.97). Together, these findings indicate that CD73 and A2AR have opposing prognostic effects, although cases involving CD73 or A2AR expression share some clinicopathological features.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.